In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biolinerx (BLRX – Research Report), with a price target of $19.00. The company's shares closed last Wednesday at $1.52, close to its 52-week low of $1.34. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -22.3% and a 22.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Biolinerx has an analyst consensus of Moderate Buy, with a price target consensus of $19.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-biolinerxs-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
BioLineRx (NASDAQ:BLRX)
Gráfico Histórico do Ativo
De Nov 2022 até Dez 2022 Click aqui para mais gráficos BioLineRx.
BioLineRx (NASDAQ:BLRX)
Gráfico Histórico do Ativo
De Dez 2021 até Dez 2022 Click aqui para mais gráficos BioLineRx.